UCB agreed to acquire Neurona for up to $1.2 billion, aiming to broaden beyond its small-molecule epilepsy base. The deal is designed to diversify its seizure treatment portfolio with a potentially one-off cell therapy in early testing for a hard-to-treat form of common epilepsy. For investors, the structure signals UCB’s continued willingness to fund platform-adjacent modalities where trial timelines may be long but upside can be material if efficacy and durability hold. The acquisition also reflects a broader shift in epilepsy portfolios toward advanced therapies addressing refractory patient populations and limitations of existing pharmacotherapy.